Journey Medical targets expanded Emrosi coverage and EBITDA growth through 2026 amid robust prescription demand

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• Planning to increase sales force to be ramped up no later than the first part of Q3

  60% confidence

• Emrosi achieved $14.7 million in net sales during the 3 quarters it was commercially available in 2025

  60% confidence

• 2025 was a milestone year with successful launch of Emrosi

  60% confidence

• Total net product revenue growth was 11% with gross margin improvement of nearly 3.5 percentage points versus 2024

  60% confidence

• One or two product launches likely in the second half of 2026 with expenses already included in budget

  60% confidence

• Approximately 100 million commercial covered lives have access to Emrosi

  60% confidence

• Prescription volume for Emrosi grew nearly 50% sequentially in Q4 versus Q3

  60% confidence

• Company expects improved reimbursement rates, reduced reliance on co-pay bridging program, and increase in Emrosi sales and operating margin expansion in 2026

  60% confidence

• March prescriptions rebounded and Q1 prescriptions expected to surpass Q4 numbers

  60% confidence

• Journey is well positioned to execute business plan and grow sales and profitability with current resources

  60% confidence

• Total revenues for 2025 were $61.9 million, representing a 10% increase compared to $56.1 million for 2024

  60% confidence

• Over 3,500 unique dermatology prescribers had written at least one script for Emrosi by year end

  60% confidence

• Gross to net expected to improve gradually quarter-over-quarter throughout 2026 as national formularies adopt Emrosi

  60% confidence

Cited in these Via News reports

• Global CFOs Redirect $20M+ Toward AI Infrastructure as Power Grid Capacity Becomes Primary Constraint →